BACKGROUND: The purpose of this study was to examine the synthesis and elimination of phosphatidylethanol (PEth) 16:0/18:1 and 16:0/18:2 following the consumption of alcohol among 56 light and heavy drinkers. METHODS: A transdermal alcohol monitor was used to promote alcohol absence 7 days prior, and 14 days after, alcohol consumption in the laboratory. Participants consumed a 0.4 or 0.8 g/kg dose of alcohol in 15 minutes. Blood and breath samples were collected before, at various times up to 360 minutes postconsumption, and 2, 4, 7, 11, and 14 days after alcohol consumption. Initial rates of PEth synthesis, 360 minutes area under the PEth pharmacokinetic curves (AUCs), and elimination half-lives were determined. RESULTS: (i) Nonzero PEth levels were observed before alcohol dosing for most participants, despite 7 days of alcohol use monitoring; (ii) 0.4 and 0.8 g/kg doses of alcohol produced proportional increases in PEth levels in all but 1 participant; (iii) the initial rate of synthesis of both PEth homologues did not differ between the 2 doses, but was greater for PEth 16:0/18:2 than PEth 16:0/18:1 at both doses; (iv) the mean AUC of both PEth homologues was higher at 0.8 g/kg than at 0.4 g/kg; (v) the mean AUC of 16:0/18:2 was greater than that of PEth 16:0/18:1 at both alcohol doses; (vi) the mean half-life of PEth 16:0/18:1 was longer than that of PEth 16:0/18:2 (7.8 ± 3.3 [SD] days and 6.4 ± 5.0 [SD] days, respectively); and (vii) there were no sex differences in PEth 16:0/18:1 or 16:0/18:2 pharmacokinetics. CONCLUSIONS: The results of this study support the use of PEth 16:0/18:1 and 16:0/18:2 as biomarkers for alcohol consumption. Because of consistent pharmacokinetic differences, the levels of these 2 PEth homologues may provide more information regarding the quantity and recentness of alcohol consumption than either alone.
BACKGROUND: The purpose of this study was to examine the synthesis and elimination of phosphatidylethanol (PEth) 16:0/18:1 and 16:0/18:2 following the consumption of alcohol among 56 light and heavy drinkers. METHODS: A transdermal alcohol monitor was used to promote alcohol absence 7 days prior, and 14 days after, alcohol consumption in the laboratory. Participants consumed a 0.4 or 0.8 g/kg dose of alcohol in 15 minutes. Blood and breath samples were collected before, at various times up to 360 minutes postconsumption, and 2, 4, 7, 11, and 14 days after alcohol consumption. Initial rates of PEth synthesis, 360 minutes area under the PEth pharmacokinetic curves (AUCs), and elimination half-lives were determined. RESULTS: (i) Nonzero PEth levels were observed before alcohol dosing for most participants, despite 7 days of alcohol use monitoring; (ii) 0.4 and 0.8 g/kg doses of alcohol produced proportional increases in PEth levels in all but 1 participant; (iii) the initial rate of synthesis of both PEth homologues did not differ between the 2 doses, but was greater for PEth 16:0/18:2 than PEth 16:0/18:1 at both doses; (iv) the mean AUC of both PEth homologues was higher at 0.8 g/kg than at 0.4 g/kg; (v) the mean AUC of 16:0/18:2 was greater than that of PEth 16:0/18:1 at both alcohol doses; (vi) the mean half-life of PEth 16:0/18:1 was longer than that of PEth 16:0/18:2 (7.8 ± 3.3 [SD] days and 6.4 ± 5.0 [SD] days, respectively); and (vii) there were no sex differences in PEth 16:0/18:1 or 16:0/18:2 pharmacokinetics. CONCLUSIONS: The results of this study support the use of PEth 16:0/18:1 and 16:0/18:2 as biomarkers for alcohol consumption. Because of consistent pharmacokinetic differences, the levels of these 2 PEth homologues may provide more information regarding the quantity and recentness of alcohol consumption than either alone.
Authors: Alexandra Schröck; Annette Thierauf-Emberger; Stefan Schürch; Wolfgang Weinmann Journal: Int J Legal Med Date: 2016-09-05 Impact factor: 2.686
Authors: Donald M Dougherty; Nathalie Hill-Kapturczak; Yuanyuan Liang; Tara E Karns; Sarah L Lake; Sharon E Cates; John D Roache Journal: Addict Disord Their Treat Date: 2015-09
Authors: Marisa Lopez-Cruzan; John D Roache; Nathalie Hill-Kapturczak; Tara E Karns-Wright; Donald M Dougherty; Jesus J Sanchez; Wouter Koek; Martin A Javors Journal: Alcohol Clin Exp Res Date: 2018-08-26 Impact factor: 3.455
Authors: Vincent J Maffei; Robert W Siggins; Meng Luo; Meghan M Brashear; Donald E Mercante; Christopher M Taylor; Patricia Molina; David A Welsh Journal: J Infect Dis Date: 2021-03-29 Impact factor: 5.226
Authors: Judith A Hahn; Pamela M Murnane; Eric Vittinghoff; Winnie R Muyindike; Nneka I Emenyonu; Robin Fatch; Gabriel Chamie; Jessica E Haberer; Joel M Francis; Saidi Kapiga; Karen Jacobson; Bronwyn Myers; Marie Claude Couture; Ralph J DiClemente; Jennifer L Brown; Kaku So-Armah; Mark Sulkowski; Gregory M Marcus; Sarah Woolf-King; Robert L Cook; Veronica L Richards; Patricia Molina; Tekeda Ferguson; David Welsh; Mariann R Piano; Shane A Phillips; Scott Stewart; Majid Afshar; Kimberly Page; Kathleen McGinnis; David A Fiellin; Amy C Justice; Kendall Bryant; Richard Saitz Journal: Alcohol Clin Exp Res Date: 2021-05-07 Impact factor: 3.928
Authors: Leonieke J Breunis; Sophie Wassenaar; Barbara J Sibbles; Ab A Aaldriks; Hilmar H Bijma; Eric A P Steegers; Birgit C P Koch Journal: BMC Pregnancy Childbirth Date: 2021-04-30 Impact factor: 3.007
Authors: Majid Afshar; Kenneth Baker; Josefine Corral; Erin Ross; Erin Lowery; Richard Gonzalez; Ellen L Burnham; Rachael A Callcut; Lucy Z Kornblith; Carolyn Hendrickson; Elizabeth J Kovacs; Cara Joyce Journal: Ann Surg Date: 2021-03-10 Impact factor: 13.787
Authors: Marisa Lopez-Cruzan; Nicole A R Walter; Jesus J Sanchez; Brett C Ginsburg; Wouter Koek; Vanessa A Jimenez; Kathleen A Grant; Martin A Javors Journal: Alcohol Clin Exp Res Date: 2021-04-19 Impact factor: 3.455
Authors: Candice Z Ulmer; Jeremy P Koelmel; Christina M Jones; Timothy J Garrett; Juan J Aristizabal-Henao; Hubert W Vesper; John A Bowden Journal: Lipids Date: 2020-06-09 Impact factor: 1.646
Authors: Gary M Reisfield; Scott A Teitelbaum; Joseph T Jones; Dana Mason; Max Bleiweis; Ben Lewis Journal: J Anal Toxicol Date: 2021-11-09 Impact factor: 3.367